Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microneedle versus subcutaneous adalimumab delivery in healthy volunteers
NL-OMON46242Active, not recruiting
- Sponsor
- Leiden University Medical Center
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial of adalimumab in autoimmune disease, autoinflammatory disease (AID) and juvenile idiopathic arthritis (JIA) (2 arms), sponsored by Leiden University Medical Center. Primary endpoints: Serious and non-serious adverse events, Vital signs and clinical laboratory assessments and 16 more. Started May 2018; status: active, not recruiting.
02
Drugs
03
Conditions
autoimmune diseaseautoinflammatory disease (AID)juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on NL-OMON46242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46242.